Maruishi Pharmaceutical Co., Ltd. (Headquarters: Osaka City, Osaka Prefecture, President and CEO: Katsuto Inoue, hereinafter referred to as Maruishi Pharmaceutical) and FRONTEO Co., Ltd. (Headquarters: Minato-ku, Tokyo, Representative Director and President: Masahiro Morimoto, hereinafter referred to as FRONTEO) are drug manufacturers. repositioning^{* 1}We would like to inform you that we have concluded a contract regarding outsourcing.

　Maruishi Pharmaceutical's main targets are perioperative/acute/emergency medical care, infection control, and supportive care (cancer supportive care), as well as unmet medical needs including peripheral areas.^{* 2}In order to meet the^{* 3}We are engaged in consistent research and development activities, including related studies, non-clinical studies, clinical studies, and even post-marketing drug development.

　By combining FRONTEO's AI drug discovery business "Drug Discovery AI Factory" (hereinafter referred to as DDAIF) with the drug development knowledge and technology that we have accumulated over the years, we will be able to create new treatments through drug repositioning of drugs for which safety information is known. We hope that drug development will be accelerated.

　At DDAIF, FRONTEO is developing new services that support the efficiency, acceleration, and success rate of drug discovery by utilizing in-house developed AI specialized in hypothesis generation for drug research and development.Hypotheses in drug research and development predict mechanisms based on the relationship between target molecules and diseases, and play an extremely important role in various phases from target discovery, which is the most upstream stage of development, to clinical trials and market launch. That's one. At DDAIF, we generate and propose hypotheses based on evidence, including the search and evaluation of highly novel target molecules and biomarkers, elucidation of mechanisms, proposal of indications, and evaluation of seeds, according to customer needs.

　The in-house developed AI applications and analysis methods used in this project will be widely used not only for new drug development, but also for drug repositioning, personalized medicine, and research related to diseases with high unmet medical needs, which cannot be achieved using conventional approaches. Enables innovative and creative drug discovery approaches.

　Through this project, Maruishi Pharmaceutical and FRONTEO will accelerate drug discovery research and business and contribute to improving the quality of medical care and patients' QOL.

*1 Diversion of existing drugs to other diseases
*2 Needs for new drugs and treatments for diseases for which no effective treatments have been found.
*3 Chemistry, Manufacturing and Control

■About Maruishi Pharmaceutical　URL:https://www.maruishi-pharm.co.jp/
Maruishi Pharmaceutical Co., Ltd. was founded in 1888 as a manufacturer of Japanese Pharmacopoeia pharmaceuticals (basic drugs).Utilizing the technology, knowledge, and know-how that we have cultivated over our 130-year history, we contribute to medical care by conducting a wide range of research, development, and dissemination of pharmaceuticals, with the primary goal of improving the quality of life of patients.
In recent years, based on our business base in the perioperative medical field and infection control field, we have also been expanding into acute phase/emergency medical care and supportive medical care (cancer supportive care).

■ About FRONTEO　URL:https://www.fronteo.com/
FRONTEO is a data analysis company that provides various AI solutions and services using the in-house developed AI engine "KIBIT". Based on the philosophy of "providing solutions that do not overlook risks and opportunities buried in records and realizing fairness in the information society," extract meaningful and important information from vast amounts of text data and complex networks. Our strengths are natural language processing and network analysis technologies that support advanced judgments by experts.We are developing businesses in the areas of legal tech AI, business intelligence, life science AI, and economic security, and contributing to solving various corporate and social issues. Founded in August 2003, listed on Tokyo Stock Exchange Mothers (currently Tokyo Stock Exchange Growth) on June 8, 2007.The company operates in Japan, the United States, South Korea, and Taiwan.Acquisition of first-class medical device manufacturing and sales business license, notification of controlled medical device sales business.Capital 6 thousand yen (as of March 26, 3,042,317).

*FRONTEO, KIBIT, and Drug Discovery AI Factory are registered trademarks of FRONTEO in Japan.